Welcome to our dedicated page for Arcellx news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on Arcellx stock.
Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biotechnology company dedicated to transforming cell therapy by developing innovative immunotherapies for patients with cancer and other incurable diseases. By harnessing advanced scientific techniques, Arcellx is reimagining cell therapy to be safer, more effective, and widely accessible.
Arcellx's flagship product candidate, CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel), is a BCMA-specific CAR-modified T-cell therapy aimed at treating relapsed or refractory multiple myeloma (rrMM). The innovative D-Domain binding technology used in anito-cel is designed to enhance target specificity and binding affinity, potentially improving therapeutic outcomes. In ongoing clinical studies, anito-cel has demonstrated remarkable efficacy, achieving a 100% overall response rate and a 76% complete response rate in patients with poor prognostic factors.
Arcellx is also making strides with its ARC-SparX platform, which includes two clinical-stage programs: ACLX-001 for rrMM and ACLX-002 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. These programs highlight Arcellx's commitment to developing dosable and controllable CAR-T therapies that address unmet medical needs.
In collaboration with Kite, a Gilead Company, Arcellx is co-developing and co-commercializing anito-cel for the treatment of multiple myeloma. This partnership not only strengthens their financial footing but also accelerates the clinical development and potential commercial launch of anito-cel. Kite's extensive experience in CAR T-cell therapy manufacturing and commercialization complements Arcellx's cutting-edge research, creating a synergistic force in the cell therapy landscape.
Arcellx has a robust pipeline and a solid financial position, with cash, equivalents, and marketable securities expected to fund operations into 2027. The company is on track to initiate the global Phase 3 trial iMMagine-3 in the second half of 2024, aimed at further validating anito-cel's efficacy and safety compared to standard of care treatments in a diverse patient population.
For more detailed information, visit www.arcellx.com and follow Arcellx on X (formerly Twitter, @arcellx) and LinkedIn.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm specializing in immunotherapies for cancer and other severe diseases, will participate in the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on April 20, 2023, at 1:00 p.m. ET. This session will be a fireside chat featuring company management.
A live webcast will be available on Arcellx's website, and a replay will be accessible for 30 days post-event. Arcellx focuses on innovative cell therapies, including its lead candidate, CART-ddBCMA, targeting relapsed or refractory multiple myeloma, currently in a Phase 2 trial. The FDA has granted it several designations, including Fast Track and Orphan Drug.
Arcellx, Inc. (NASDAQ: ACLX) reported significant business highlights and financial results for Q4 and the year ended December 31, 2022. The company signed a strategic collaboration with Kite to co-develop CART-ddBCMA for multiple myeloma, receiving $225 million upfront and a $100 million equity investment. In clinical trials, CART-ddBCMA showed a 100% overall response rate in a Phase 1 trial. However, R&D expenses surged to $149.6 million for 2022 due to non-cash expenses and increased headcount. Arcellx ended 2022 with $254.8 million in cash, positioning it well for further pipeline development.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused on innovative immunotherapies for cancer, announced participation in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 1:00 p.m. ET. A live webcast will be available on Arcellx's website in the Investors section, with a replay accessible for 30 days. Arcellx is advancing its lead candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma and is also developing the dosable CAR-T therapy, ARC-SparX. The company holds multiple FDA designations for its therapies, reinforcing its commitment to advancing cell therapy.
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology firm focused on innovative immunotherapies for cancer, announced its participation in two upcoming investor conferences. The Guggenheim Oncology Conference will feature a fireside chat on February 9, 2023, at 11:20 a.m. ET, while the SVB Securities Global Biopharma Conference will be held virtually on February 16, 2023, at 3:00 p.m. ET. Live webcasts will be available on Arcellx's website with replays archived for 30 days. Arcellx is advancing its lead candidate, CART-ddBCMA, in pivotal trials for multiple myeloma, supported by several FDA designations.
On January 29, 2023, Kite, a Gilead company (NASDAQ: GILD), and Arcellx (NASDAQ: ACLX) announced the completion of a global strategic collaboration to co-develop and co-commercialize CART-ddBCMA, a late-stage product candidate for treating relapsed or refractory multiple myeloma. Currently in a Phase 2 pivotal trial, CART-ddBCMA leverages a novel synthetic binder technology. The collaboration will allow Kite to commercialize the therapy outside the U.S., while both companies will advance the asset in the U.S. This partnership aims to address the urgent need for effective therapies in treating multiple myeloma, an incurable cancer for most patients.
Kite and Arcellx have announced a global collaboration to co-develop the CART-ddBCMA therapy for relapsed or refractory multiple myeloma. Kite will provide an upfront payment of $225 million and a $100 million equity investment. The companies will share development and commercialization costs, splitting U.S. profits 50/50. The partnership aims to address the significant unmet need in multiple myeloma treatment.
The transaction is expected to close in Q1 2023 and may reduce Gilead's EPS by approximately $0.16. The collaboration capitalizes on Kite's leadership in cell therapy and Arcellx's innovative approach.
Arcellx (NASDAQ: ACLX) reported promising long-term results from the CART-ddBCMA Phase 1 expansion trial, where 100% of patients achieved an overall response rate. Of 38 evaluable patients, 71% reached complete or stringent complete response (CR/sCR). No severe toxicities were noted at the recommended Phase 2 dose of 115 million CAR+ T cells. Additionally, the company initiated the iMMagine-1 Phase 2 trial and the Phase 1 trial for ACLX-002 targeting acute myeloid leukemia and myelodysplastic syndromes. The developments indicate a strong commitment to advancing innovative cancer therapies.
Arcellx and Kite, a Gilead Company, have entered into a strategic collaboration to co-develop and commercialize CART-ddBCMA, a late-stage cell therapy for relapsed or refractory multiple myeloma. Arcellx will receive an upfront payment of $225M, a $100M equity investment, and potential contingent payments up to $3.9B. The companies will share U.S. profits 50/50 while Arcellx earns royalties on sales outside the U.S. The collaboration aims to accelerate patient access to innovative therapies.
Arcellx, Inc. (NASDAQ: ACLX) reported its third-quarter 2022 financial results, highlighting the initiation of the pivotal iMMagine-1 Phase 2 study for CART-ddBCMA aimed at treating relapsed multiple myeloma. The company has $280.8 million in cash, sufficient to fund operations for the next 12 months. R&D expenses surged to $83.5 million, primarily due to a one-time $63.1 million non-cash expense related to Lonza manufacturing services. The net loss for the quarter was $92.9 million, marking a significant increase from $17.1 million in Q3 2021.
FAQ
What is the current stock price of Arcellx (ACLX)?
What is the market cap of Arcellx (ACLX)?
What is Arcellx, Inc.?
What is the lead product candidate of Arcellx?
What are the latest clinical trial updates for anito-cel?
Who are Arcellx's key partners?
What is ARC-SparX?
What is the financial outlook for Arcellx?
What designations has anito-cel received?
What is the iMMagine-3 trial?
How can I get more information about Arcellx?
What recent collaborations has Arcellx announced?
